143 related articles for article (PubMed ID: 11119918)
1. MMF-based regimen in maintenance therapy after kidney transplantation.
Wu MJ; Shu KH; Cheng CH; Chen CH; Lian JD
Transplant Proc; 2000 Nov; 32(7):1748-50. PubMed ID: 11119918
[No Abstract] [Full Text] [Related]
2. Evaluation of various immunosuppressive regimes in second renal transplants.
Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
[No Abstract] [Full Text] [Related]
3. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis.
Kumar MS; Cahill K; Kumar AM; Panigrahi D; Seirka D; Singleton R; al-Abdullah IH; Laskow DA
Transplant Proc; 1998 Jun; 30(4):1351-2. PubMed ID: 9636549
[No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
Fabrega AJ; Corwin CL; Hunsicker L
Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
Tsang WK; Tong KL; Yeung S; Lee W; Chan HW
Transplant Proc; 2000 Nov; 32(7):1755-6. PubMed ID: 11119921
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
[No Abstract] [Full Text] [Related]
7. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
Park K; Kim SI; Moon JI; Kim YS; Kim MS
Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
Suhail SM; Vathsala A; Lou HX; Woo KT
Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
[No Abstract] [Full Text] [Related]
10. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
[No Abstract] [Full Text] [Related]
11. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
[No Abstract] [Full Text] [Related]
12. Mycophenolate mofetil-induced ischemic colitis.
Kim HC; Park SB
Transplant Proc; 2000 Nov; 32(7):1896-7. PubMed ID: 11119990
[No Abstract] [Full Text] [Related]
13. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
14. Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches.
Abramowicz D; Wissing KM; Broeders N
Transplant Proc; 2000 Feb; 32(1A Suppl):3S-5S. PubMed ID: 10686309
[No Abstract] [Full Text] [Related]
15. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups.
Cho S; Hodge E; Navarro M
Transplant Proc; 1999; 31(1-2):322-3. PubMed ID: 10083126
[No Abstract] [Full Text] [Related]
16. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.
Carl S; Dörsam J; Mandelbaum A; Staehler G; Wiesel M
Transplant Proc; 1998 Jun; 30(4):1236-7. PubMed ID: 9636502
[No Abstract] [Full Text] [Related]
17. Indications for mycofenolate mofetil therapy after liver transplantation.
Platz KP; Mueller AR; Neuhaus P
Transplant Proc; 1997 Nov; 29(7):2880-1. PubMed ID: 9365601
[No Abstract] [Full Text] [Related]
18. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
19. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.
Smak Gregoor PJ; Hesse CJ; van Gelder T; van der Mast BJ; IJzermans JN; van Besouw NM; Weimar W
Transplant Proc; 1998 Jun; 30(4):1192-3. PubMed ID: 9636482
[No Abstract] [Full Text] [Related]
20. Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone.
Khauli RB; Medawar WA; Habbal AA; Birbari AE; Daouk MM; Abdelnoor AM; Uwaydah M; Rahman Bizri A; Sanjad S; Ayvazian PJ; Lovewell T; Stoff JS; Yang Fan P; Bigwood P; Harland R
Transplant Proc; 2001 Aug; 33(5):2776-7. PubMed ID: 11498156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
